Lynkogen Inc.

Lynkogen's vision is to develop transformative protein therapeutics to address the unmet needs in both rare and prevalent metabolic diseases

  • Stage Product In Development
  • Industry Biotechnology
  • Location East Windsor, NJ, US
  • Currency USD
  • Founded March 2016
  • Employees 2
  • Incorporation Type C-corp

Company Summary

Lynkogen Inc. is a pre-clinical stage biotech company whose vision is to develop transformative therapies that can simultaneously target multiple triggers that lead to serious metabolic diseases. Lynkogen's is developing innovative fusion proteins to address the unmet need in complex metabolic diseases. Lynkogen recently acquired from Alteogen Inc. rights to A1AT based fusion protein technology to address NASH and Type 1 Diabetes.

Team

  • Arun Swaminathan
    Chief Executive Officer

    Dr. Arun Swaminathan is a commercial leader with deep experience in shaping strategy for several cardiovascular/metabolic and immunological assets including ELIQUIS®, NULOJIX ® and ORENCIA® while at Bristol Myers Squibb. While at Covance he headed marketing for their clinical business. He also has direct experience in business development and in moving products from pre-IND to commercialization.

  • NARAYANAN HARIHARAN
    Chief Scientific Officer

    Dr. Narayanan Hariharan is an accomplished industry leader, with extensive experience in drug discovery and translational medicine. His areas of expertise are cardio-metabolic, inflammatory and liver diseases, the area of focus for Lynkogen.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free